XNASTERN
Market cap393mUSD
Jan 15, Last price
4.63USD
1D
1.31%
1Q
-38.27%
IPO
-76.60%
Name
Terns Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.35%
Rev. gr., 5y
%
Revenues
0k
Net income
-90m
L+49.49%
CFO
-67m
L+37.23%
Earnings
Mar 12, 2025
Profile
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 103,439 | 63,061 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (103,439) | (63,061) | ||||
NOPBT Margin | ||||||
Operating Taxes | 239 | 358 | ||||
Tax Rate | ||||||
NOPAT | (103,678) | (63,419) | ||||
Net income | (90,210) 49.49% | (60,345) 20.31% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 41,611 | 167,739 | ||||
BB yield | -9.00% | -45.73% | ||||
| Debt | ||||||
Debt current | 1,206 | 661 | ||||
Long-term debt | 603 | 1,749 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 1,206 | 1,071 | ||||
Net debt | (261,631) | (280,704) | ||||
| Cash flow | ||||||
Cash from operating activities | (67,390) | (49,109) | ||||
CAPEX | (52) | (275) | ||||
Cash from investing activities | (37,987) | (22,272) | ||||
Cash from financing activities | 41,951 | 167,496 | ||||
FCF | (102,903) | (64,177) | ||||
| Balance | ||||||
Cash | 263,440 | 283,114 | ||||
Long term investments | ||||||
Excess cash | 263,440 | 283,114 | ||||
Stockholders' equity | (332,641) | (243,235) | ||||
Invested Capital | 590,420 | 521,383 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 71,259 | 36,033 | ||||
Price | 6.49 -36.25% | 10.18 43.99% | ||||
Market cap | 462,472 26.08% | 366,816 105.32% | ||||
EV | 200,841 | 86,112 | ||||
EBITDA | (102,558) | (62,029) | ||||
EV/EBITDA | ||||||
Interest | 2,042 | |||||
Interest/NOPBT | ||||||